Limb girdle muscular dystrophy (LGMD) is not a single disease but a group of genetic conditions that cause progressive weakness and wasting of the muscles closest to the center of the body, specifically the shoulders, upper arms, hips, and thighs. There are more than 30 recognized subtypes, each linked to a different gene mutation, and they vary widely in severity, age of onset, and speed of progression. Some forms begin in childhood and advance quickly; others appear in adulthood and progress slowly over decades.
Which Muscles Are Affected First
The hallmark of LGMD is weakness in the “girdle” muscles, the rings of muscle around the shoulder and hip joints that anchor your limbs to your trunk. Early on, this typically shows up as difficulty raising your arms overhead, climbing stairs, or getting up from a chair or the floor. The weakness is symmetrical, meaning it affects both sides of the body roughly equally.
Because the hip muscles weaken early, many people develop a distinctive waddling gait combined with an inability to lift the heels fully off the ground. The abdomen also weakens, which causes the lower back to curve inward (a lordotic posture) and the stance to widen for balance. Over time, weakness spreads outward to muscles farther from the trunk, though the pattern depends on the specific subtype. One form called Miyoshi myopathy, for example, starts unusually in the calves rather than the hips, making it hard to walk on tiptoes before any hip weakness appears.
How LGMD Is Inherited
LGMD subtypes fall into two broad categories based on how they’re passed down. Dominantly inherited forms (historically called LGMD1, now relabeled with a “D” prefix) require only one copy of a mutated gene from one parent to cause disease. Recessively inherited forms (historically LGMD2, now labeled with an “R” prefix) require two copies, one from each parent. Recessive forms are more common and generally more severe.
The mutated genes code for proteins that play structural or repair roles in muscle cells. When those proteins are missing or defective, muscle fibers become fragile and break down faster than the body can rebuild them. Two of the most commonly affected genes produce proteins called calpain-3 and dysferlin. Calpain-3 mutations cause one of the most frequently diagnosed subtypes worldwide, while dysferlin mutations are responsible for the Miyoshi myopathy variant and a related hip-girdle form.
Rate of Progression
How quickly LGMD advances varies enormously, even among family members who share the same mutation. As a general rule, earlier onset tends to mean faster progression, while people whose symptoms begin in adulthood often follow a slower course.
Some concrete benchmarks help illustrate the range. In the calpain-3 subtype, progression tends to be slow: people typically use a wheelchair 11 to 28 years after symptoms first appear. The sarcoglycan subtypes (affecting a group of structural proteins in the muscle membrane) progress more rapidly, with loss of independent walking often occurring between ages 12 and 16, sometimes as early as 10. Most people with LGMD live well into adulthood, though many do not reach a full life expectancy, and a significant number become wheelchair dependent within 20 to 30 years of symptom onset.
Heart and Lung Involvement
LGMD is primarily a skeletal muscle disease, but certain subtypes carry real risks for the heart and lungs. The distinction matters because cardiac problems in LGMD can be managed if caught early but can become dangerous if ignored.
Subtypes caused by sarcoglycan mutations and one caused by a protein called FKRP tend to develop a form of heart failure where the heart muscle stretches and weakens (dilated cardiomyopathy). A subtype linked to the lamin A/C gene takes a different cardiac path, primarily causing irregular heart rhythms and electrical conduction problems that can lead to fainting or sudden cardiac events. In contrast, the common calpain-3 and dysferlin subtypes rarely cause significant heart disease.
Because of these risks, the American Heart Association recommends a full cardiac evaluation at the time of LGMD diagnosis, including an ECG and echocardiogram. For subtypes with known cardiac risk, repeat evaluations every two years are standard when results are normal, and annually when any abnormalities are found. Respiratory function also declines in some subtypes as the muscles that expand the chest weaken, so periodic breathing tests are part of ongoing monitoring.
Daily Management and Exercise
There is currently no cure for LGMD, so management focuses on preserving function, preventing complications, and maintaining quality of life for as long as possible. Physical therapy and occupational therapy form the backbone of care. Physical therapy emphasizes keeping joints mobile, preventing the permanent tightening of tendons and muscles (contractures), and, where possible, strengthening larger muscle groups. Occupational therapy zeroes in on practical skills: hand function, work tasks, and the daily activities that let someone remain independent.
Exercise is important but requires some caution. High-intensity or exhaustive exercise can accelerate muscle damage in people with LGMD. The general guidance is to avoid pushing to the point of exhaustion, stay well hydrated, and steer clear of very heavy resistance work. Swimming and water-based exercise are widely recommended because buoyancy supports the body and reduces the strain that gravity places on weakened muscles, while still allowing meaningful strengthening and cardiovascular conditioning.
Assistive devices enter the picture at different stages depending on the subtype and the individual. Ankle braces or orthotic inserts can help with foot drop and gait instability early on. Powered wheelchairs or scooters eventually become necessary for many people, and home modifications like grab bars, ramps, and shower seats help maintain independence as mobility declines.
Getting a Diagnosis
LGMD can be tricky to pin down because the early symptoms, difficulty climbing stairs, trouble lifting things overhead, unexplained muscle pain, overlap with many other conditions. The diagnostic process usually starts with blood tests showing elevated levels of an enzyme called creatine kinase, which leaks out of damaged muscle cells. Genetic testing has become the definitive tool: a multigene panel can identify the specific mutation and subtype, which matters because prognosis, cardiac risk, and potential eligibility for clinical trials all depend on the exact genetic cause.
In some cases, a muscle biopsy is still used to look for missing or reduced proteins in the muscle tissue, particularly when genetic results are inconclusive. The average time from first symptoms to confirmed diagnosis can stretch for years, partly because LGMD is rare and partly because its early signs are easy to attribute to other causes.
Gene Therapy on the Horizon
Researchers are actively testing gene replacement therapies for specific LGMD subtypes. The most advanced effort targets the sarcoglycan subtype LGMD2E/R4, using a viral delivery system to introduce a functional copy of the missing gene directly into muscle cells. A multicenter clinical trial of a therapy called bidridistrogene xeboparvovec has been evaluating this approach, though enrollment is currently closed as the study progresses through later phases. Similar strategies are in earlier development for other subtypes. These therapies aim to address the root cause rather than just manage symptoms, but none have yet received regulatory approval for clinical use.